VASAMED Receives CE Mark For AcQtrac(TM) System

MINNEAPOLIS, Jan. 4 /PRNewswire-FirstCall/ -- VASAMED , a leader in noninvasive, hemodynamic assessment technology, announced that it received CE Mark for its new AcQtrac(TM) System. The AcQtrac System provides real-time measurements of hemodynamic parameters that allow physicians to more effectively manage a broad range of cardiovascular patients.

"Each year, cardiovascular disease contributes to nearly half of all deaths in Europe and the European Union, which represents approximately 6 million people. Overall, heart disease is estimated to cost Europe euro 169 billion annually," said Paulita LaPlante, president and CEO of VASAMED. "The AcQtrac System's rapid, noninvasive cardiovascular assessment can be a cost-effective alternative for a market focused on earlier diagnosis and treatment as part of their overall health policy objectives."

Also cleared for use in the United States by the FDA earlier this year, the AcQtrac System is the next generation in noninvasive cardiovascular assessment that provides accurate, repeatable and reliable cardiac and circulatory health information. It relies on a unique graphical waveform that represents the mechanical function of the cardiovascular system and provides vital information to quickly assess conditions such as congestive heart failure or to monitor treatment outcomes such as those provided by drug therapy.

"The AcQtrac(TM) ICG impedance cardiograph has provided us an invaluable tool in the management of congestive heart failure in a clinical setting," said James Leibsohn, MD, an interventional cardiologist at St. Luke's Medical Center, Milwaukee, Wisconsin. "We are now able to accurately determine peripheral resistance and cardiac output in an outpatient setting and, for the first time, adjust medications precisely on the basis of accurate hemodynamic measurements."

In addition to the AcQtrac System, VASAMED manufactures the SensiLase(TM) PAD 3000 and LASERDOPP(TM) PV2000 System for quantitative evaluation of microcirculatory perfusion in patients with chronic foot ulcers, diabetes and other peripheral arterial disease. Laser Doppler technology, coupled with proprietary algorithms to measure skin perfusion pressure and pulse volume, assist physicians in evaluating microvascular health and improving blood flow and wound healing in their patients. The accuracy of the skin perfusion pressure measurement is not affected by edema, anemia, medial calcification or certain other conditions that limit the usefulness of other measurement technologies. VASAMED has also developed a system for the measurement of sublingual CO2, which can be used in a variety of hemodynamic diagnostic applications.

For more information about VASAMED, visit http://www.vasamed.com .

CONTACT: Wes Peterson, CFO of VASAMED, +1-952-944-5857 ext. 542

Web site: http://www.vasamed.com/